Breast Cancer Update

View Top 200 Chart

Back to Rankings Page

Health & Fitness
**Breast Cancer Update**

Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology-oncology fellows ongoing access to the perspectives and opinions of national and international breast cancer clinical investigators.

Latest Episodes:

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 4 with Dr Sara M Tolaney Oct 10, 2026

Show notes

Featuring perspectives from Dr Sara M Tolaney, including the following topics:

Management of adverse events associated with TROP2-targeting antibody-drug conjugates (0:00)
Managing brain metastases in triple-negative breast cancer (6:30)
EGFR x HER3-directed bispecific antibodies for metastatic triple-negative breast cancer (mTNBC) (9:11)
PD-1/PD-L1 x VEGF-directed bispecific antibodies for mTNBC (12:31)

CME information and select publications

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 3 with Dr Sara M Tolaney Oct 09, 2026

Show notes

Featuring perspectives from Dr Sara M Tolaney, including the following topics:

Mechanistic effects and potential resistance mechanisms of antibody-drug conjugates (0:00)
First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients eligible for immunotherapy (7:13)
First-line treatment of mTNBC in patients ineligible for immunotherapy (13:02)
Antibody-drug conjugates for previously treated HER2-low metastatic breast cancer (19:15)

CME information and select publications

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 2 with Dr David W Cescon Sep 22, 2026

Show notes

Featuring perspectives from Dr David W Cescon, including the following topics:

Clinical treatment of BRCA-mutated metastatic triple-negative breast cancer (0:00)
CNS activity of TROP2-directed antibody-drug conjugates (5:36)
Autoimmune considerations with immunotherapy (10:09)
Treatment of oligoprogressive advanced breast cancer (17:31)

CME information and select publications

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 1 with Dr David W Cescon Sep 21, 2026

Show notes

Featuring perspectives from Dr David W Cescon, including the following topics:

First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients not eligible for immunotherapy (0:00)
First-line treatment of mTNBC in patients eligible for immunotherapy (12:05)
Adverse events (19:39)

CME information and select publications

Breast Cancer — Reviewing Key Presentations from the 2026 ASCO Annual Meeting Sep 15, 2026

Show notes

Featuring perspectives from Dr Aditya Bardia, Dr Kevin Kalinsky and Dr Joyce O'Shaughnessy, including the following topics:

Introduction (0:00)
Hormone Receptor-Positive Breast Cancer — Dr Kalinsky (1:18)
HER2-Positive Breast Cancer — Dr Bardia (42:46)
Triple-Negative Breast Cancer — Dr O'Shaughnessy (1:01:41)

CME information and select publications

ER-Positive, HER2-Positive Metastatic Breast Cancer — Patterns of Care Among Community Oncologists Sep 03, 2026

Show notes

Featuring perspectives from Dr Lisa A Carey and Dr Maha Hussain, including the following topics:

Introduction (0:00)
HER2 History (1:32)
Cases from the GMO Survey (7:06)
Biology and Selection of First-Line Therapy for HR-Positive, HER2-Positive Metastatic Breast Cancer (mBC) — Dr Mahtani (19:56)
Faculty Case Presentations (31:37)
Patterns of Care Survey — Part 1 (38:26)
Optimizing the Use of Up-Front Maintenance Therapy for HER2-Positive mBC — Dr Carey (44:53)
Faculty Case Presentations (54:13)

CME information and select publications

Metastatic Triple-Negative Breast Cancer — Patterns of Care Aug 28, 2026

Show notes

Featuring perspectives from Prof Peter Schmid and Dr Melinda Telli, including the following topics:

Introduction: TROP2-Targeting Antibody-Drug Conjugates (ADCs) for Metastatic Triple-Negative Breast Cancer (0:00)
First-Line Therapy (PD-L1 Negative) (6:53)
First-Line Therapy (PD-L1 Positive) (23:40)
Second-Line Therapy (Sequencing) (34:08)
Adverse Events with TROP2-Targeting ADCs (43:43)

CME information and select publications

HR-Positive Metastatic Breast Cancer — Year in Review Series on Relevant New Datasets and Advances in the PI3K/AKT/mTOR Pathway Aug 24, 2026

Show notes

Featuring perspectives from Dr Virginia Kaklamani and Dr Hope S Rugo, including the following topics:

Introduction: San Antonio Memories (0:00)
PI3K/AKT/PTEN Alterations and Therapies (7:18)
Capivasertib (20:22)
Gedatolisib (34:08)
Inavolisib (47:07)
New Agents and Ongoing Trials (52:34)

CME information and select publications

For Oncology Nurses: Oral Selective Estrogen Receptor Degraders in Breast Cancer — Proceedings from the 2026 Annual ONS Congress Aug 18, 2026

Show notes

Featuring perspectives from Ms Blanca Ledezma, Dr Marissa Marti-Smith, Dr Heather McArthur and Dr Ruth M O'Regan, moderated by Dr McArthur, including the following topics:

Introduction (0:00)
Current Clinical Role of Oral Selective Estrogen Receptor Degraders (SERDs) in HR-Positive Metastatic Breast Cancer (3:37)
Practical Considerations with Oral SERDs (15:42)
Potential Role of Combination Approaches with Oral SERDs (26:31)
Gastrointestinal Adverse Events Documented with Oral SERDs (38:17)
Potential Role of Early Therapeutic Switching After Detection of an Emergent ESR1 Mutation (46:51)
Other Class-Effect Toxicities Associated with Oral SERDs (1:00:53)
Emerging Utility of Adjuvant Oral SERDs (1:10:16)
Unique Toxicities Associated with 1 or More Oral SERDs (1:19:17)

CME information and select publications

For Oncology Nurses: Targeting the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer — Proceedings from the 2026 Annual ONS Congress Aug 10, 2026

Show notes

Featuring perspectives from Dr Reva Basho, Ms Kelly Fischer, Ms Melissa Rikal and Dr Seth Wander, moderated by Dr Wander, including the following topics:

Introduction (00:00)
Identification of Appropriate Candidates for Agents Targeting the PI3K/AKT/mTOR Pathway (3:45)
Role of Inavolisib in HR-Positive Metastatic Breast Cancer (mBC) (13:00)
Strategies to Prevent and Manage Hyperglycemia (27:02)
Clinical Utility of Capivasertib for HR-Positive mBC (38:09)
Mitigation and Management of Gastrointestinal Adverse Events (51:05)
Management of Dermatologic Adverse Events (59:58)
Potential Role of Gedatolisib in the Management of HR-Positive mBC (1:08:42)
Monitoring and Management of Cytopenias (1:21:23)

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected